A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 675 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... December 21, 2020 Frederick National Laboratory for Cancer Research: A Unique Resource for the... March 28, 2023 Little Girl Declared Cancer-Free For The Holidays Following 2 Years Of... December 24, 2021 Load more HOT NEWS Meet the teams tackling 5 challenges in children’s and young people’s... Malaria Vaccine Approved by W.H.O. Could Save Tens Of Thousands Of... Why people and culture matter in research March is Multiple Myeloma Action Month
